The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL.
Jae Hong Park
No relevant relationships to disclose
Isabelle Riviere
Consultant or Advisory Role - JUNO THERAPEUTICS
Stock Ownership - JUNO THERAPEUTICS
Xiuyan Wang
No relevant relationships to disclose
Shirley Bartido
No relevant relationships to disclose
Michel Sadelain
Consultant or Advisory Role - JUNO THERAPEUTICS
Stock Ownership - JUNO THERAPEUTICS
Renier J. Brentjens
Consultant or Advisory Role - JUNO THERAPEUTICS
Stock Ownership - JUNO THERAPEUTICS